Clinical Trials Browser

Terminated × Cholangiocarcinoma × Dermatologic × Clear all

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT05432193 2025-06-25

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Phase 1 Terminated

20 enrolled

DermatologicGastrointestinalHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Melanoma, Sarcoma, Colorectal Neoplasms, Cholangiocarcinoma

NCT05501912 2024-11-29

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Phase 1 Terminated

20 enrolled

DermatologicGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Cholangiocarcinoma

NCT02714374 2024-08-06

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Phase 1 Terminated

5 enrolled

DermatologicGastrointestinalOther solid neoplasmThoracic

Gallbladder Neoplasms, Melanoma, Mesothelioma, Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

Phase 1 Terminated

53 enrolled

CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT04644315 2023-08-07

ALpha-T

Phase 2 Terminated

1 enrolled 5 charts

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Renal Cell, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Phase 1 Terminated

5 enrolled

DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Clinical Trials

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ALpha-T

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.